Stockscreener 앱 받기
16.23
6.46%
-1.12
시간 외 거래:
16.35
0.12
+0.74%
전일 마감가:
$17.35
열려 있는:
$17.35
하루 거래량:
1.28M
Relative Volume:
2.52
시가총액:
$1.60B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.12%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.18
$17.54
1주일 범위
$16.18
$17.80
52주 변동 폭
$14.62
$18.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
16.23 | 1.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360
Definium Therapeutics Announces New Employee Inducement GrantsFebruary 3, 2026 - BioSpace
Definium Therapeutics stock hits 52-week high at 18.19 USD By Investing.com - Investing.com Nigeria
LSD therapy biotech Definium sued for alleged trade secret theft | Business Information & News | FE - Westlaw Today
LSD therapy biotech Definium sued for alleged trade secret theft - Reuters
Company Researching LSD Applications Faces Trade Secrets Litigation in Delaware Federal Court - Law.com
Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week HighShould You Buy? - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.19 USD - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Definium stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Definium stock - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Jefferies Financial Group - Defense World
Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? - Yahoo Finance
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones - Yahoo Finance
Definium Therapeutics Adds Commercial Leader As Phase 3 Milestones Approach - Sahm
Commit To Buy Definium Therapeutics At $10, Earn 21.9% Annualized Using Options - Nasdaq
Jefferies Initiates Coverage on Definium Therapeutics With Buy Rating, $30 Price Target - marketscreener.com
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating - Investing.com India
Definium Therapeutics appoints Roger Adsett to board of directors By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Critical Contrast: Definium Therapeutics (NASDAQ:DFTX) vs. Tetra Bio-Pharma (OTCMKTS:TBPMF) - Defense World
Definium Therapeutics (DFTX) Expands Board with New Appointment - GuruFocus
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
Definium Therapeutics Expands Board, Appoints New Director - TipRanks
Definium Therapeutics appoints Roger Adsett to board of directors - Investing.com
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Yahoo Finance
Will Definium's ‘Rerouting Minds’ LSD Education Push Recast DFTX’s Science-First Psychedelic Narrative? - simplywall.st
Certain Pre-funded warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2026. - marketscreener.com
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
DFTX Stock Price and Chart — NASDAQ:DFTX - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Defense World
A Look At Definium Therapeutics (DFTX) Valuation After Rerouting Minds Campaign Highlights Psychedelic LSD Programs - simplywall.st
Definium Therapeutics (FRA:MMQ0) Momentum Rank : 2 (As of Jan. 24, 2026) - GuruFocus
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com India
RBC Raises Price Target on Definium Therapeutics to $36 From $20, Keeps Outperform, Speculative Risk - marketscreener.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Deinium Therapeutics (DFTX) Is Up 11.5% After Psychedelic Rebrand And DT120 Roadmap Reveal Has The Bull Case Changed? - Sahm
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com South Africa
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium Therapeutics Inc (DFTX) 재무 분석
Definium Therapeutics Inc (DFTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (DFTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Dec 26 '25 |
Sale |
13.15 |
25,791 |
339,072 |
778,477 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '25 |
Sale |
13.15 |
11,276 |
148,244 |
282,576 |
1.24%
0.19%
자본화:
|
볼륨(24시간):